Summary
The pharmacokinetics of 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ara-A) in plasma and its biologically active 5′-triphosphate (F-ara-ATP) in leukemic cells obtained from the peripheral blood and bone marrow was evaluated in patients with hematologic malignancies subsequent to the first dose of 20–125 mg/m2 per day for 5 days of F-ara-A 5′-monophosphate (F-ara-AMP) administered as an IV bolus over 30 min. The terminal half-lives of elimination of both F-ara-A (8 h) in plasma and intracellular F-ara-ATP (15 h) were not dependent upon the dose of F-ara-AMP. The area under the concentration x time curves for F-ara-A and F-ara-ATP, on the other hand, were increased in proportion to the prodrug dose. There was a high correlation between F-ara-ATP levels in circulating leukemic cells and those in bone marrow cells aspirated at the same time. DNA-synthetic capacity of leukemic cells was inversely related to the associated F-ara-ATP concentration. A linear trend was noted when F-ara-ATP levels in pretreatment peripheral blood leukemic cells incubated with F-ara-A in vitro were compared with the amount of F-ara-A that was incorporated into nucleic acids. Finally, F-ara-ATP concentrations were three times higher in bone marrow cells from patients with lymphomatous bone marrow involvement than from those without evidence of marrow disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Avramis VI, Plunkett W (1983) 2-Fluoro-ATP: A toxic metabolite of 9-β-D-arabinofuranosyl-2-fluoroadenine. Biochem Biophys Res Commun 113: 35
Brink JJ, LePage GA (1964) Metabolic effects of 9-β-D-arabinofuranosylpurines in ascites tumor cells. Cancer Res 24: 312
Brockman RW, Schabel FM Jr, Montgomery JA (1977) Biologic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-D-arabinofuranosyladenine. Biochem Pharmacol 26: 2193
Brockman RW, Cheng Y-C, Schabel FM Jr, Montgomery JA (1980) Metabolism and chemotherapeutic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res 40: 3610
Cass CE, Au-Yeung TH (1976) Enhancement of 9-β-D-arabinofuranosyl-adenine cytotoxicity to mouse leukemic L1210 in vitro by 2′-deoxycoformycin. Cancer Res 36: 1486
DeSonza JJV, Grever MR, Neidhart JA, Staubus AE, Malspeis L (1984) Comparative pharmacokinetics and metabolism of fludarabine phosphate (NSC 312887) in man and dog. Proc Am Assoc Cancer Res 25: 361
Doering AM, Keller J, Cohen SS (1966) Some effects of D-arabinosyl nucleosides on polymer synthesis in mouse fibroblasts. Cancer Res 26: 2444
Dow LW, Bell DE, Poulakas L, Fridland A (1980) Differences in metabolism and cytotoxicity between 9β-D-arabinofuranosyladenin and 9-β-D-arabinofuranosyl-2-fluoradenine in human leukemia lymphoblasts. Cancer Res 40: 1404
Grever MR, Lieby JM, Kraut EH, Neidhart JA, Malspeis L, Blacerzak SP (1984) A phase I investigation of 2-fluoro-ara-AMP in refractory leukemia. Blood 64 [Suppl]: 569
Hutton JJ, Von Hoff DD, Kuhn J, Phillips J, Hersh M, Clark G (1984) Phase I clinical investigation of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res 44: 4183
Kantarjian H, Barlogie B, Plunkett W, Velasquez W, McLaughlin P, Riggs S, Cabanillas F (1983) High-dose cytosine arabinoside in non-Hodgkin's lymphoma. J Clin Oncol 1: 689
LePage GA, Khaliq A, Gottlieb JA (1973) Studies of 9-β-D-arabinofuranosyladenine in man. Drug Metab Dispos 1: 756
LePage GA, Worth LS, Kimball AP (1976) Enhancement of the antitumor activity of arabinofuranosyladenine by 2′-deoxycoformycin. Cancer Res 36: 1481
Liliemark JO, Plunkett W, Dixon DO (1985) The relationship of 1-β-D-arabinofuranosylcytosine in plasma to 1-β-D-arabinofuranosylcytosine 5′-triphosphate levels in leukemic cells during treatment with high dose 1-β-D-arabinofuranosylcytosine. Cancer Res 45: 5952
Malspeis L, DeSonza JJV, Staubus AE, Neidhart JA, Grever MR (1984) Pharmacokinetics of 2-F-ara-AMP in man during a phase I clinical trial. Invest New Drugs. 2: 110
Mittleman A, Ashikari R, Ahmed T, Charwanki V, Friedland M, Arlin Z (1985) Phase II trial of 2-fluoro-ara-AMP (fludarabine phosphate) in patients with advanced breast cancer. Proc Am Assoc Cancer Res 26: 170
Montgomery JA, Hewson K (1969) Nucleosides of 2-fluoroadenin. J Med Chem 12: 498
Montgomery JA, Clayton SD, Shortney AT (1979) An improved procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoradenine. J Heterocycl Chem 16: 157
Noker PE, Duncan GF, El Dareer SM, Hill DL (1983) Disposition of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-phosphate in mice and dogs. Cancer Treat Rep 67: 445
Plunkett W, Chubb S (1985) Toxicity, metabolism, and incorporation into DNA and RNA of arabinosyl-2-fluoroadenine (F-ara-A). Proc Am Assoc Cancer Res 26: 19
Plunkett W, Cohen SS (1975) Two approaches that increase the activity of analogs of adenine nucleotides in animal cells. Cancer Res 35: 1547
Plunkett W, Chubb S, Alexander L, Montgomery JA (1980a) Comparison of the toxicity and metabolism of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res 40: 2349
Plunkett W, Hug V, Keating MJ, Chubb S (1980b) Quantitation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-D-arabinofuranosylcytosine therapy. Cancer Res 40: 588
Plunkett W, Benjamin RS, Keating MJ, Freireich EJ (1982) Modulation of 9-β-D-arabinofuranosyladenine 5′-triphosphate and deoxyadenosine during therapy with 9-β-D-arabinofuranosyladenine. Cancer Res 42: 2092
Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ (1985) Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 12 [Suppl 3]: 20
Preisler HD, Rustum Y, Priore RL (1985) Relationship between leukemic cell retention of cytosine arabinoside triphosphate and duration of remission in patients with acute nonlymphocytic leukemia. Eur J Cancer Clin Oncol 21: 23
Rustum YM, Preisler HD (1979) Correlation between leukemic cell retention of 1-β-D-arabinofuranosylcytosine 5′-triphosphate and response to therapy. Cancer Res 39: 42
Schabel FM Jr (1968) The antiviral activity of 9-β-D-arabinofuranosyladenine (ara-A). Chemotherapy 13: 321
Skipper HE, Schabel FM Jr (1984) Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect. Cancer Treat Rep 68: 43
Tseng WC, Derse D, Cheng Y-C, Brockman RW, Bennett LL Jr (1982) In vitro biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol 21: 474
Warrell RP Jr, Berman E, Gee TS, Kempin SJ (1985) Phase I–II clinical trial of fludarabine phosphate in acute leukemia. Proc Am Assoc Cancer Res 26: 179
White EL, Shaddix SD, Brockman RW, Bennett LL Jr (1982) Comparisons of the actions of 9-β-D-arabinofuranosyl-2-fluoroadenine on target enzymes from mouse tumor cells. Cancer Res 42: 2260
Author information
Authors and Affiliations
Additional information
Supported in part by grants CA28153 and CA32839 from the National Cancer Institute, United States Department of Health and Human Services
Rights and permissions
About this article
Cite this article
Danhauser, L., Plunkett, W., Keating, M. et al. 9-β-D-Arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother. Pharmacol. 18, 145–152 (1986). https://doi.org/10.1007/BF00262285
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00262285